Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool.

Recruiting now

Conditions studied: Characteristics Disease, Metastatic Cancer, Solid Tumor

In brief

A prospective observational trial of patients with metastatic cancer of various entities which aims at both clarifying the significance of liquid biopsy and establishing a foundation for translational research.

Key facts

Study ID

NCT05245136

Run by

University Hospital Augsburg

People needed

3000

Starts

2021-03-29

Expected to finish

2030-03-01

Last updated by the study team

2026-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent
• Age ≥ 18 years
• Histopathologically confirmed metastatic or locally advanced cancer
• No curative treatment options, except for germ cell tumors
• Written Agreement to be followed up at Augsburg University Medical Center
• Signed written informed consent for the Biobank Augsburg (Biobank-A)
• Willing to undergo treatment according to standard of care
• Availability or anticipated availability of tumor tissue at time point of inclusion
• Anticipated life expectancy of at least 3 months at time point of trial inclusion

You may not qualify if…

• Psychological condition that would preclude informed consent
• Additional tumor treatment between acquisition of tumor tissue and trial inclusion

Where it is running

• University Hospital Augsburg — Augsburg, Bavaria, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.